더바이오 10월 27일 주요뉴스 [https://www.thebionews.net/edit/webzine.html?idxno=671](https://www.thebionews.net/edit/webzine.html?idxno=671) ● [ESMO] “美 뚫은 ‘리픽투’ 12월 상업화…‘리보세라닙’, 빠르면 연내 미국 허가” [https://www.thebionews.net/news/articleView.html?idxno=29475](https://www.thebionews.net/news/articleView.html?idxno=29475) ● [ESMO] GSK·中 한소제약, B7-H3 ADC 골육종 3상서 진행·사망 위험 67%↓ [https://www.thebionews.net/news/articleView.html?idxno=29477](https://www.thebionews.net/news/articleView.html?idxno=29477) ● [ESMO] MSD, ‘사시투주맙 티루모테칸’ 자궁내막암 3상서 사망 위험 32%↓ [https://www.thebionews.net/news/articleView.html?idxno=29480](https://www.thebionews.net/news/articleView.html?idxno=29480) ● 국내 제약바이오, ‘뷰티’도 M&A로 키운다…해외 유통·생산망 확보 경쟁 [https://www.thebionews.net/news/articleView.html?idxno=29471](https://www.thebionews.net/news/articleView.html?idxno=29471) ● 한미약품 “릴리·제넨텍 기술수출 비결은 데이터 차별화·조직 실행력” [https://www.thebionews.net/news/articleView.html?idxno=29530](https://www.thebionews.net/news/articleView.html?idxno=29530) ● 한미약품, 3분기 만에 올해 매출 1조2000억 돌파…안정적 성장세 지속(종합) [https://www.thebionews.net/news/articleView.html?idxno=29529](https://www.thebionews.net/news/articleView.html?idxno=29529) ● 노연홍 회장 “제약바이오 글로벌 도약, 개방형 혁신·전략적 협력 필수” [https://www.thebionews.net/news/articleView.html?idxno=29526](https://www.thebionews.net/news/articleView.html?idxno=29526) ● RET 표적치료제 ‘레테브모’, 4년여 만에 급여…“약제 효과에 의심 여지 없어” [https://www.thebionews.net/news/articleView.html?idxno=29509](https://www.thebionews.net/news/articleView.html?idxno=29509) ● 이니바이오, 보툴리눔 톡신 제제 ‘이니보’ 中 허가…국산 톡신 중 세 번째 진출 [https://www.thebionews.net/news/articleView.html?idxno=29523](https://www.thebionews.net/news/articleView.html?idxno=29523) ● [ESMO] 한미약품, 경구 EZH1·EZH2 이중저해제 고형암 1상서 부분관해 추가 [https://www.thebionews.net/news/articleView.html?idxno=29507](https://www.thebionews.net/news/articleView.html?idxno=29507) ● [ESMO] 한미약품, ‘PD-L1·4-1BB 이중항체’ 고형암 임상1상서 부분관해 2명 [https://www.thebionews.net/news/articleView.html?idxno=29505](https://www.thebionews.net/news/articleView.html?idxno=29505) ● 바로팜, 약국 플랫폼 기업서 종합 헬스케어사로 도약…브랜드 사업 키운다 [https://www.thebionews.net/news/articleView.html?idxno=29511](https://www.thebionews.net/news/articleView.html?idxno=29511) ● 셀트리온, 3분기 실적 ‘역대 최대’…매출 1조5755억원·영업익 5253억원 [https://www.thebionews.net/news/articleView.html?idxno=29494](https://www.thebionews.net/news/articleView.html?idxno=29494) ● ‘통합 동아제약’ 첫 실적 공개…3분기 매출 4310억원, 전년比 12.7% 증가 [https://www.thebionews.net/news/articleView.html?idxno=29510](https://www.thebionews.net/news/articleView.html?idxno=29510) ● 동아에스티, 3Q 매출 4.1% 증가 2065억원…2분기 연속 매출 2000억원 돌파 [https://www.thebionews.net/news/articleView.html?idxno=29506](https://www.thebionews.net/news/articleView.html?idxno=29506) ● 에스티팜, 상업화 품목 매출 확대 ‘순항’…3Q 매출 976억원·영업익 157억원 [https://www.thebionews.net/news/articleView.html?idxno=29512](https://www.thebionews.net/news/articleView.html?idxno=29512) ● 지투지바이오 “중국 UBT 계약, 기술이전 위한 사전 평가…본계약과 구분” [https://www.thebionews.net/news/articleView.html?idxno=29527](https://www.thebionews.net/news/articleView.html?idxno=29527) ● [ESMO] MSD, ‘키트루다’ 단독요법 자궁내막암 3상서 진행·사망 위험 43%↓ [https://www.thebionews.net/news/articleView.html?idxno=29481](https://www.thebionews.net/news/articleView.html?idxno=29481) ● [ESMO] 면역항암제 3개월 간격 투여에 사망 위험 2배↑…임상3상 조기 중단 [https://www.thebionews.net/news/articleView.html?idxno=29479](https://www.thebionews.net/news/articleView.html?idxno=29479) ● 강스템바이오텍, ‘오스카’ 2a상 CSR 수령…통증·관절기능 개선 효과 확인 [https://www.thebionews.net/news/articleView.html?idxno=29515](https://www.thebionews.net/news/articleView.html?idxno=29515) ●Sky Labs drives commercialization of ‘no-correction blood pressure ring,’ speeding evolution of ‘cuffless’ technology [https://www.thebionews.net/news/articleView.html?idxno=29532](https://www.thebionews.net/news/articleView.html?idxno=29532) ●Celltrion expands European pharmacy channels, speeding up Q4 sales of high-profit product lines [https://www.thebionews.net/news/articleView.html?idxno=29531](https://www.thebionews.net/news/articleView.html?idxno=29531) ●Ahn-gook Pharm speeds into medical aesthetics, setting up skin care division [https://www.thebionews.net/news/articleView.html?idxno=29525](https://www.thebionews.net/news/articleView.html?idxno=29525) ●GI Innovation set to collect KRW 4.6 billion in technology fees from Japan’s Maruho for ‘GI-301’ [https://www.thebionews.net/news/articleView.html?idxno=29524](https://www.thebionews.net/news/articleView.html?idxno=29524) ●[ESMO] LigaChem Biosciences: “‘LCB02A’ takes on first-line gastric cancer treatment, aiming to replace ‘Vyloy’” [https://www.thebionews.net/news/articleView.html?idxno=29522](https://www.thebionews.net/news/articleView.html?idxno=29522) ●[ESMO] Skin side effects fall from 39% to 18% when ‘Rybrevant SC’ and ‘Leclaza’ combination is preceded by pre-administration [https://www.thebionews.net/news/articleView.html?idxno=29521](https://www.thebionews.net/news/articleView.html?idxno=29521) ●[ESMO] 5 of 12 Presidential Session cases are new drugs – “Support for Korea’s new modalities must continue” [https://www.thebionews.net/news/articleView.html?idxno=29520](https://www.thebionews.net/news/articleView.html?idxno=29520) *제약바이오 10월 27일 아침 유튜브 라디오 뉴스(매일 아침 업로드) [https://www.youtube.com/watch?v=vlbLNUbtDVY](https://www.youtube.com/watch?v=vlbLNUbtDVY)